Rosiglitazone (trade name Avandia, GlaxoSmithKline) is an antidiabetic drug in
the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding ...
Dec 16, 2015 ... The REMS is no longer necessary to ensure that the benefits of rosiglitazone
medicines outweigh their risks.
Dec 16, 2015 ... Rosiglitazone and other similar medications for diabetes may cause or worsen
congestive heart failure (condition in which the heart is unable ...
Learn about clinical pharmacology for the drug Avandia (Rosiglitazone Maleate).
Dec 16, 2015 ... The FDA pulls the plug on its prior risk evaluation and mitigation strategy for
rosiglitazone-containing type 2 diabetes medicines.
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is
marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone ...
Rosiglitazone is used to treat a type of diabetes mellitus called type 2 diabetes. It
may be used alone or with other medicines such as metformin or sulfonylurea ...
Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its
effect on cardiovascular morbidity and mortality has not been determined.
Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive
heart ... Boxed Warning, AVANDIA-Rosiglitazone Medicines. Access Program ...
The DDD for troglitazone is based on combination therapy. The DDDs for
rosiglitazone and pioglitazone are based on monotherapy.